Some believe that shifting the surveillance testing group to Singapore from Groton is also part of Pfizer's strategy to further cut costs. When asked about whether this move is part of Pfizer's cost cutting strategy, the company responded by saying "Pfizer operates in a very competitive and challenging environment. This environment requires us to continually look at how we do business to determine if we can improve efficiency and reduce costs by more effectively using our resources. Our decision was made based on a number of factors, including proximity to contractors whose products are being tested, geography and operating costs. By providing surveillance testing services in Singapore, Pfizer can more closely support this important growth market and suppliers in Asia, and align with the location of PGS' external supply organization in Asia."

The company has been taking serious measures in terms of cost adjustments as, last month the company had also announced that it would sell its nutrition unit to Nestle for $11.9 billion. Whether or not the relocation to Singapore is part of the company's strategy to bring down costs, the company has been hard hit with Lipitor going off patent and the company is taking this issue quite seriously.